Objective: Menopause is a risk factor for fracture; thus, menopause age may affect bone mass and fracture rates. We compared bone mineral density (BMD) and fracture rates among healthy postmenopausal women with varying ages at self-reported nonsurgical menopause.
F ractures are a significant cause of morbidity and mortality among aging individuals. Mortality rates are reported to be as high as 30% within the first year of a spine or hip fracture, 1, 2 and increased morbidity is largely related to diminished quality of life caused by fracture-induced disability. 3 Multiple risk factors for decreased bone mass, and thus for predisposition to fractures, have been identified, including (among others) female sex, advancing age, low body weight, white race, nulliparity, alcohol consumption, tobacco use, vitamin D deficiency, and low dietary calcium intake. 4 Menopause is associated with increased risk for fractures in women, with multiple factors playing a role, including advancing age, loss of the antiresorptive effect of estrogen on bone, changes in body composition, changes in activity level, ethnicity, and parity. 5, 6 Furthermore, among women who experience menopause at very young ages, optimal bone accrual may not have occurred, which may also contribute to increased fracture risk later in life. Indeed, minimizing fracture risk is an important aspect of the longterm clinical care of postmenopausal women.
The mean age at menopause is approximately 52 years; however, many women experience menopause at slightly younger ages. Women who enter menopause earlier may be at greater-than-expected risk for fracture for their chronological age because of a longer duration of postmenopausal bone loss and, in some cases, reduced bone accrual. It is wellestablished that young (premenopausal) women with syndromic forms of premature ovarian failure (defined clinically as ovarian failure or insufficiency before age 40 y) have low age-related bone mineral density (BMD). [7] [8] [9] [10] [11] [12] [13] On the other hand, many other factors also play a role in determining ultimate BMD and fracture risk in postmenopausal women; thus, menopause age may have less overall impact during older age. Whether or not and to what extent otherwise healthy postmenopausal women without syndromic forms of premature menopause but who experience menopause earlier than the mean age have differences in bone mass or fracture risk attributable to menopause age have not been previously investigated.
The Women's Health Initiative Observational Study (WHI OS) is a large prospective cohort study designed to investigate risks for chronic diseases, including risk for fractures, in relatively healthy postmenopausal women. Two of the study's primary outcome measures were occurrence of fractures and, in a small subset, absolute BMD and change in BMD across time. Here, we analyzed WHI OS data to determine whether age at menopause among women in the WHI OS cohort is associated with fracture occurrence and/or BMD.
METHODS
A total of 93,676 postmenopausal women were recruited between October 1, 1993, and December 31, 1998 , at 40 WHI study sites in the United States. Detailed descriptions of WHI eligibility criteria, study design, and methods have been previously published. 14 Briefly, women aged 50 to 79 years who had no medical comorbidities that precluded survival for at least 3 years after study entry were eligible to participate. Each study participant provided a written informed consent form through the approving Institutional Review Board (IRB) at her respective study site. Local IRBs at each study site, the National Institutes of Health, and the coordinating center IRB approved the protocols.
At study enrollment, the following information was collected from all participants using standardized questionnaires: demographic information; complete personal medical history, including medication history and current medication use, smoking status, alcohol consumption, and recreational physical activity level; and family history. Participants were instructed to bring all of their medications (including overthe-counter and supplement medications) to the clinic for verification of use. Current or prior use of hormone therapy (HT) was carefully documented. Information on baseline risk for fractures (such as family history or personal history of fractures) was also collected using standardized questionnaires. This included assessment of total daily calcium intake from dietary sources and supplements. Updated information was collected annually through mailed follow-up questionnaires. Physical examination was performed at study entry to assess height, weight, and blood pressure, and again after 3 years.
For all participants in the WHI, fracture occurrences were recorded yearly. Fractures were categorized by site: hip/ pelvis/upper leg, lower leg/ankle/knee, foot, upper arm/ shoulder/elbow, lower arm/wrist/hand, and spine/tailbone. For every participant, the first occurrence of a hip fracture was adjudicated and confirmed by WHI physicians; the first occurrences of all other fracture types were based on selfreport and were not adjudicated. A small subgroup of WHI OS women underwent dual-energy x-ray absorptiometry (DXA) scans of the lumbar spine (total spine), total hip, and whole body at the time of study entry, and again at the 3-year, 6-year, and 9-year study visits. Among women who underwent DXA scans, the mean duration of follow-up was 7 years. Three of the 40 WHI study sites (Pittsburgh, PA; Birmingham, AL; Tucson, AZ) performed DXA scans (QDR2000, 2000 þ , or 4500W; Hologic Inc, Bedford, MA), with low interscan variability among the three sites (<1.5% for spine, 4.8% hip, and 1.7% for linearity) based on weekly phantom scans performed as a quality control measure.
In this secondary analysis of the WHI OS, we investigated the impact of self-reported age at nonsurgical menopause on cumulative fracture occurrence and change in BMD across time. Menopause age was defined as a woman's age at the time of her final menstrual period; this definition helps us avoid confounding our analyses with data from women with oligorrhea or amenorrhea attributable to other causes. Of the original 93,676 women in the WHI OS, we excluded 3,951 women who had missing information on menopause status at screening. To further avoid confounding our data with women who were exposed to estrogen after the reported age at menopause (because of either surgical menopause or HT use), we also excluded 68,014 WHI OS women (i) who had undergone total abdominal hysterectomy (TAH) and/or bilateral salpingo-oophorectomy (BSO; unless performed at an age older than the reported age at menopause); (ii) with self-reported history of HT at baseline; or (iii) with selfreported use of HT during the study. Of the original 93,676 women in the WHI OS, 21,711 women met all of our inclusion criteria (ie, not missing menopause information, no TAH and/ or BSO, no history of HT use at baseline, or no reported use of HT during the study) and were included in this analysis. These women were divided into three groups based on reported age at nonsurgical menopause: (i) menopause before age 40 years; (ii) menopause between ages 40 and 49 years; and (iii) menopause at age 50 years or older. These age categories were prespecified in the WHI OS. Clinically speaking, these age categories also divide women into those who underwent menopause at the population mean age (!50 y) and those who experienced menopause at earlier ages. A small subset of the 21,711 eligible women in our study (n ¼ 1,351; 6.2%) had at least one DXA scan during the course of the study. This is similar to the percentage of women in the entire WHI OS cohort who had BMD data (6,482 of 93,676 women; 6.9%); thus, the subgroup of women in our substudy who had available BMD data adequately represents our study population compared with the entire WHI OS cohort. DXA results were used to compare changes in BMD during the study period among the three menopause age groups.
Because more than 70% of all women in the WHI OS with self-reported menopause before age 40 years also reported past or current HT use, we also compared demographics and risk factors for osteoporosis between uterus-intact women with the earliest self-reported age at menopause (before age 40 y) who reported current or past use of HT (who were excluded from our primary analysis) and uterus-intact women who underwent menopause before age 40 years but did not report current or past HT use (our primary cohort) to determine whether baseline risk factors in the non-HT group may have contributed to any differences found.
Statistical analyses
Baseline demographics were summarized by age at menopause (<40, 40-49, and !50 y). For women who underwent menopause before age 40 years, baseline demographics were also summarized by the presence or absence of any HT use. For continuous variables, means, SDs, and ranges are calculated. For categorical variables, frequencies and percentages are reported.
Our primary aim was to compare risk of first fracture at the hip (adjudicated) and risk of first fracture at any site (nonadjudicated) among the three specified menopause age groups. We considered time from enrollment (days) to first adjudicated hip fracture and time from enrollment (days) to any fracture (ie, adjudicated and nonadjudicated fractures) as separate primary outcomes. For all fracture types, we have records only of the first occurrence of each type; therefore, we present analyses on time to first fracture during the observation period. Cumulative hazard plots using time (days) to first fracture were generated, and Cox models were applied to the data to assess the impact of menopause age on risk of fracture. Multivariable models were adjusted for the following participant factors: age at enrollment, body weight, ethnicity, smoking status, alcohol consumption, calcium intake, vitamin D intake, history of bisphosphonate use, history of glucocorticoid use, history of diabetes, total energy expenditure from recreational physical activity (metabolic equivalent of task hours/week), self-reported number of falls in the previous 12 months, and personal history of any fracture at the time of screening, all of which are associated with fracture risk in postmenopausal women. A summary of these variables, by menopause age, is shown in Table 1 . Owing to the small number of women with available BMD data, we were unable to adjust for BMD in our multivariable model; therefore, we cannot conclude that any differences in fracture risk among the menopause groups are independent of differences in BMD. For all models, there were no significant two-way interactions with any of the covariates and menopause age. Scaled Schoenfeld residuals were examined; for models involving time to first self-reported fracture, the interaction between time (natural log scale) and age at enrollment was included because of concerns about nonproportionality. Estimated hazard ratios (HRs) with 95% CIs were calculated.
To correct for disparity in sample sizes among the three menopause groups (<40 y, n ¼ 524; 40-49 y, n ¼ 6,626; !50 y, n ¼ 14,561), we repeated our multivariable analyses using propensity score methods to match the number of women who underwent menopause before age 40 years to the number of women who underwent menopause at ages 40 to 49 years and the number of women who underwent menopause at age 50 years or older. We developed a propensity score based on a multinomial logistic model using all of the demographic factors in Table 1 . We matched 524 women who underwent menopause before age 40 years with 524 women who underwent menopause at ages 40 to 49 years and 524 women who underwent menopause at age 50 years or older separately using nearest-neighbor matching without replacement and a conservative caliper of 0.01. HRs and 95% CIs from the Cox models using the matched sample were calculated using robust standard errors, and overall conclusions from the matched set were consistent with our multivariable-adjusted models (data not shown).
Our secondary aim was to determine the association between menopause age and BMD as measured by DXA. A small subset of our original study population had at least one BMD measurement (n ¼ 1,351 participants with wholebody and/or left hip plus total spine DXA). The number of BMD measurements varied by individual; in the final multivariable models, the maximal number of measurements per individual was 4. Linear mixed-effects models were used to assess changes in whole-body, left hip, and total spine BMD as age increased for each individual, adjusting for age at enrollment, body weight, ethnicity, smoking status, alcohol consumption, calcium intake, vitamin D intake, history of bisphosphonate use, history of glucocorticoid use, history of diabetes, total energy expenditure from recreational physical activity (metabolic equivalent of task hours/week), selfreported number of falls in the previous 12 months, and personal history of any fracture at the time of screening. Age at BMD measurement was centered by subtracting the age at BMD measurement from 50 years; the intercept term in the model using these centered values therefore estimated BMD at age 50 years (the minimal age at enrollment into the EFFECTS OF MENOPAUSE AGE ON BMD AND FRACTURE WHI OS). Linear mixed-effects models were fitted to the data using the centered age at BMD measurement as time variable. The model allowed for each individual to have a separate intercept and change across time (slope) based on her available data; from these individual intercepts and slopes, overall (mean) intercept and slope for each menopause age group were calculated. In sum, we fitted linear models for each menopause age group to estimate BMD across time, using age as the primary predictor of BMD. Figure 1 thus represents changes in BMD across time (the slope of each line) for each menopause age group, as estimated from these models. From these linear mixed-effects models, we compared mean estimated BMD differences among the three menopause groups. P 0.05 was considered significant. All analyses were performed using SAS/STAT software version 9.2 (SAS Institute Inc, Cary, NC) and Stata/SE version 10.1 (2007; Stata-Corp).
RESULTS
Of 89,725 WHI OS participants who had menopause information, 68,014 women with a history of TAH, BSO, prior HT use, or current HT use were excluded, leaving 21,711 women for our primary analysis. Among the 21,711 women, 5,769 self-reported fractures during follow-up, including 593 adjudicated hip fractures. Baseline demographic characteristics of these women, grouped by menopause age, are shown in Table 1 . The demographic differences between menopause age groups shown here guided our multivariable adjustments for both primary and secondary analyses. Table 2 shows a comparison of demographics and osteoporotic risk factors between uterus-intact women who underwent menopause before age 40 years and reported no HT use (n ¼ 685) and uterus-intact women who underwent menopause before age 40 years and reported ever use of HT (and who were thus excluded from our primary analysis; n ¼ 1,899). We saw several differences in demographics and osteoporotic risk factors between these groups, including age at screening, race, smoking status, alcohol use, activity level, rates of obesity, calcium intake, vitamin D intake, and diabetes status. There were no between-group differences in time since menopause at screening, number of reported falls in the 12 months before screening, and use of glucocorticoids or bisphosphonates.
Overall, we found no significant differences in the percentage of women in each menopause group with one or more hip fractures (P ¼ 0.59) or one or more hip fractures plus all other self-reported fractures (P ¼ 0.63) during the WHI OS study period. From our primary cohort of women, cumulative hazard plots for adjudicated hip fractures ( Fig. 2A ) and all fractures (self-report plus hip; Fig. 2B ) were created using time (days) from study entry to the first fracture, after adjusting for age at screening. Age at screening was in fact the most significant predictor of both adjudicated hip fracture and any self-reported fracture for all models (P < 0.001), with older women having a higher fracture risk. In simple models with age as the only covariate, there were no significant differences in either adjudicated hip fracture or any self-reported fracture between menopause age groups (Table 3 ). However, after adjusting for other covariates and applying our multivariable model, we found that the rate of any fracture among women who reported menopause before age 40 years was greater than the fracture rate among women who underwent menopause at age 50 years or older (HR, 1.21; 95% CI, 1.02 to 1.44; P ¼ 0.03; Table 3 ). Owing to the small number of women with available BMD data, we were unable to determine whether these differences in fracture risk were independent of differences in BMD using this model. In the small subset of women in whom BMD assessments were performed, most participants had two to three BMD measurements (range, one to five BMD measurements). Separate linear mixed-effects models were used to estimate changes in whole-body, left hip, and total spine BMD across time, with age as the primary predictor and all previously listed variables as covariates; estimated slopes from these models, by menopause group, are shown in Figure 1 . There were no statistically significant interactions between age at the time of initial DXA scan and menopause group (P ¼ 0.87, P ¼ 0.24, and P ¼ 0.94 for whole-body, left hip, and total spine BMD, respectively), suggesting that differences in BMD between menopause groups were consistent across age (Fig. 1) . Left hip BMD estimates in all menopause groups decreased with increasing chronological age (P < 0.01), whereas whole-body BMD estimates did not change significantly with increasing chronological age (P ¼ 0.08) and total spine BMD estimates increased with increasing age at the time of DXA scan (P < 0.01; Fig. 1 ).
EFFECTS OF MENOPAUSE AGE ON BMD AND FRACTURE
From these models, we calculated differences in estimated BMD at the whole body, left hip, and total spine among the three menopause age groups (Table 4 ). There were statistically significant decreases in estimated BMD at the left hip, total spine, and whole body as age at menopause decreased; however, there were no differences in estimated left hip BMD between women who underwent menopause before age 40 years and women who underwent menopause at ages 40 to 49 years, and no differences in estimated total spine BMD between women who underwent menopause at ages 40 to 49 years and women who underwent menopause at age 50 years or older (Table 4 ). Overall, we found significant The interaction between age group at enrollment and time (natural log scale) was included because of evidence of nonproportionality. b Multivariable models adjusted for age at enrollment, weight, ethnicity, smoking status, alcohol consumption, history of diabetes, total energy expenditure from recreational physical activity (metabolic equivalent of task hours/week), self-reported number of falls in the previous 12 months, personal history of any fracture at the time of screening, calcium intake, vitamin D intake, bisphosphonate use at screening, and glucocorticoid use at screening.
decreases in BMD or trends toward decreasing BMD with younger age at menopause. The total number of hip fractures and the total number of fractures occurring within each menopause group, in our larger primary cohort of women (Table 5 ) and in our subgroup of women with DXA data (Table 6) , are presented for comparison. Of note, there were no significant differences in the prevalence of hip or total fractures among the three menopause age groups in our larger primary cohort (P ¼ 0.59 for hip fractures and P ¼ 0.63 for total fractures; Table 5 ), nor were there differences in the prevalence of hip or total fractures among the three menopause groups in our subgroup of women for whom DXA data were collected (P ¼ 0.67 for hip fractures and P ¼ 0.24 for total fractures; Table 6 ), despite our finding of declines in BMD with decreasing menopause age.
DISCUSSION
This analysis of a large longitudinal cohort of women with standardized outcomes data evaluates, for the first time, the effects of self-reported age at nonsurgical menopause on fracture risk and BMD. In this secondary investigation of the WHI OS, we demonstrate that, among postmenopausal women who have undergone nonsurgical menopause and have never taken HT, younger self-reported age at menopause may have a negative impact on BMD and fracture risk. Absolute fracture rates did not differ by menopause age; however, in our multivariable model, we found increased HRs for fracture among women who underwent menopause before age 40 years compared with women who underwent menopause at age 50 years or later. Using a linear mixedeffects model to estimate changes in BMD at the left hip, total spine, and whole body across time, we also found that women with younger ages at menopause had lower BMD at all sites. Overall, these data suggest that younger self-reported age at menopause negatively impacts BMD and overall fracture risk during the menopausal years and, therefore, that age at menopause in women who never received HT should contribute to clinical assessments of postmenopausal fracture risk.
Cumulative hazard plots for time (days) from study entry to the first fracture were calculated in uterus-intact women without current or prior HT use because this period was considered as a known ''exposure time'' to factors that contribute to postmenopausal bone loss, including advancing age, decreased activity levels, decreased body weight, and decline in ovarian hormone production. We believe that removing HT as a confounding variable, rather than attempting to control for use of HT in a model, was justified; thus, we excluded women in all three menopause age groups who reported any past or current HT use. Of note, the mean age at screening in the WHI OS was approximately 64 years; therefore, women who experienced menopause before age 40 years had a considerably longer time between reported age at menopause and enrollment, when monitoring for fractures began (mean time, 29 y), compared with women who underwent menopause between ages 40 and 49 years (mean time, 18 y) or women who underwent menopause at age 50 years or older (mean time, 11 y). Despite these differences in exposure time, we found no differences in absolute fracture risk by menopause age. After multivariable adjustments, however, we found small decreases in BMD and increases in fracture risk among women who reported menopause before age 40 years compared with women with older age at menopause. These data thus suggest that menopause age is one clinically significant independent risk factor for fracture in the postmenopausal years and that menopause age, together with other risk factors, influences postmenopausal fracture risk in otherwise healthy women. BMD, bone mineral density. a Multivariable models adjusted for age at enrollment, body mass index, smoking status, alcohol consumption, history of diabetes, total energy expenditure (metabolic equivalent of task hours/week), number of falls in the previous 12 months, history of any fracture at the time of screening, calcium intake, vitamin D intake, bisphosphonate use at screening, glucocorticoid use at screening, and dual-energy x-ray absorptiometry scan at screening. Although our multivariable analyses demonstrated increased risk for any fracture among women who underwent menopause before age 40 years, compared with the older menopause age groups, these data may be confounded by the small number of women in the WHI OS cohort with selfreported menopause before age 40 years and no HT use (n ¼ 524). Furthermore, we found that women who underwent menopause before age 40 years and were not treated with HT (our cohort) tended to have more osteoporotic risk factors than women who underwent menopause before age 40 years and received HT (and who were thus excluded from our primary analysis). It is possible that these differences contributed, at least in part, to the increase in fracture risk in women who experienced early menopause and were never treated with HT. Our data are consistent with data on women with syndromic forms of premature ovarian failure, such as Turner's syndrome and 46XX primary ovarian insufficiency, who are at risk for decreased BMD for age, which is attributable, at least in part, to exposure to menopausal levels of estrogen at young ages 9 to 12 years. It remains to be investigated whether HT with physiologic doses of estrogen in women with nonsyndromic early age at menopause will help to maintain BMD and/or reduce fracture risk, as it has been shown to do in women with primary ovarian insufficiency and Turner's syndrome. 10, 11, 15 Interestingly, mean body mass index (BMI) in all menopause age groups was between 25 and 30 kg/m 2 (overweight; Table 1 ). Being either underweight or obese is associated with loss of BMD. 15, 16 That women in this study were overweight (as opposed to underweight or obese) as a group and that mean BMI was clinically similar among the three menopause age groups suggest that BMI differences were not responsible for the differences in BMD and fracture risk demonstrated here.
We found a higher prevalence of African-American and Hispanic women, compared with white women, among participants reporting menopause before age 40 years. Given that white race itself is a risk factor for osteoporosis and fractures, the increased prevalence of African-American and Hispanic women who underwent menopause before age 40 years would be expected to contribute to increased BMD and decreased fracture risk in this group. However, we demonstrated no differences in absolute fracture risk and-after multivariable adjustments-decreases in BMD and slightly increased HR for fracture in women with earlier menopause. Together, these data are consistent with multiple risk factors acting together to determine the ultimate fracture risk and suggest that no single risk factor may be able to independently predict postmenopausal loss of bone mass or fracture risk. Advancing chronological age was the strongest predictor of fracture risk in our cohort and was a significantly greater contributor than self-reported age at menopause.
Strengths of this study include a large cohort of healthy postmenopausal women, careful follow-up, and collection of detailed data on multiple covariates impacting bone density and fracture risk, such as physical activity, alcohol consumption, tobacco use, and use of medications such as glucocorticoids and bisphosphonates. Furthermore, the availability of comparable DXA measurements from a subset of these women across time allowed us to compare BMD among the menopause groups.
Study limitations include a lack of information on the use of medications that may have affected BMD before study entry, with the exception of prior use of HT. Second, menopause age was recorded based on participant self-report and was not confirmed with hormonal testing (ie, follicle-stimulating hormone and/or estradiol levels within menopausal range); thus, it is possible that some women reported menopause caused by prolonged amenorrhea but were not yet truly menopausal, or that menopause age was reported later than it actually occurred. Menopause age was defined as the age at the final menstrual period; thus, to the extent that menopause age was reported erroneously early or late by study participants, we expect each of our menopause age groups to be affected similarly. Third, we collected data on calcium and vitamin D intake through supplements and diet; however, we did not measure serum 25-hydroxyvitamin D levels among WHI OS participants; thus, vitamin D deficiency could not be accounted for as a potential contributor to fracture risk. In addition, we only have adjudicated data on fractures that occurred after study enrollment; thus, any fractures occurring before study entry were not included in our hazard functions. We do not believe, however, that exclusion of prior fractures has significantly impacted our results because, at enrollment, only 158 of 21,711 women included in this analysis reported an osteoporosis-related fracture before enrollment (menopause before age 40 y, 7 [1.3%]; menopause at ages 40-49 y, 43 [0.7%]; menopause at age 50 y or older, 108 [0.7%]). Finally, study power was limited by the number of WHI OS participants without prior TAH, BSO, and/or HT use who also had BMD data. The small number of women with both fracture occurrence and DXA data in our analysis prevented us from reliably including BMD as a covariate in our multivariable analyses for fracture risk; thus, we cannot be certain that differences in the HRs for fracture among the menopause age groups were independent of differences in baseline BMD. We demonstrated decreases in BMD among women with younger age at menopause, suggesting that the increase in fracture rates observed in women with younger age at menopause may be attributable, at least in part, to decreased BMD. 
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